0T20 Stock Overview
A clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Traws Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.60 |
| 52 Week High | US$29.75 |
| 52 Week Low | US$6.60 |
| Beta | 1.39 |
| 11 Month Change | -16.46% |
| 3 Month Change | -30.89% |
| 1 Year Change | -60.30% |
| 33 Year Change | -91.48% |
| 5 Year Change | -97.68% |
| Change since IPO | -99.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0T20 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 3.1% | 4.5% |
| 1Y | -60.3% | -12.1% | 13.5% |
Return vs Industry: 0T20 underperformed the German Pharmaceuticals industry which returned -12.1% over the past year.
Return vs Market: 0T20 underperformed the German Market which returned 13.5% over the past year.
Price Volatility
| 0T20 volatility | |
|---|---|
| 0T20 Average Weekly Movement | 11.6% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0T20's share price has been volatile over the past 3 months.
Volatility Over Time: 0T20's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 18 | Werner Cautreels | www.trawspharma.com |
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers.
Traws Pharma, Inc. Fundamentals Summary
| 0T20 fundamental statistics | |
|---|---|
| Market cap | €9.37m |
| Earnings (TTM) | -€122.47m |
| Revenue (TTM) | €201.95k |
46.4x
P/S Ratio-0.1x
P/E RatioIs 0T20 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0T20 income statement (TTM) | |
|---|---|
| Revenue | US$226.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$226.00k |
| Other Expenses | US$137.28m |
| Earnings | -US$137.05m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -75.03 |
| Gross Margin | 100.00% |
| Net Profit Margin | -60,641.15% |
| Debt/Equity Ratio | 0% |
How did 0T20 perform over the long term?
See historical performance and comparison